On May 15, 2014, Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), reported its financial results for the quarter ended March 31, 2014. Galmed reported a positive cash flow from financing activities of $41.9 million for the quarter ended March 31, 2014 as compared to a negative cash flow from financing activities of $20,000 for the quarter ended March 31, 2013. The positive cash flow was primarily due to the issuance of ordinary shares in its initial public offering in March 2014 for net proceeds of approximately $39.9 million and the issuance of ordinary shares in a financing round completed prior to the initial public offering in February 2014 for net proceeds of approximately $2.0 million. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), weekly performance is -1.96%. On last trading day company shares ended up $6.99. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD), distance from 50-day simple moving average (SMA50) is -29.72%.
On May 12, 2014, Recro Pharma Inc (NASDAQ:REPH), reported financial results for the first quarter ended March 31, 2014. or the first quarter of 2014, Recro Pharma reported a net loss applicable to common shareholders of $6.4 million, or $3.67 per share, compared to a net loss of $0.5 million, or $3.30 per share, for the comparable period in 2013. Recro Pharma Inc (NASDAQ:REPH), advanced 5.24% in last trading session and ended the day on $6.83. REPH, return on assets is -720.00%.
Regulus Therapeutics Inc (NASDAQ:RGLS), was downgraded byZacks from a “neutral” rating to an “underperform” rating in a research report issued to clients and investors on Tuesday,AmericanBankingNews.com reports. They currently have a $6.30 price target on the stock. Zacks‘s price target indicates a potential downside of 5.83% from the company’s current price. Regulus Therapeutics Inc (NASDAQ:RGLS), shares moved up 7.49% in last trading session and was closed at $6.89, while trading in range of $6.38 – 6.95. Regulus Therapeutics Inc (NASDAQ:RGLS), year to date (YTD) performance is -6.77%.
On May 08, 2014, ChemoCentryx Inc (NASDAQ:CCXI), announced its financial results for the first quarter ended March 31, 2014. There was no revenue recognized for the three months ended March 31, 2014, compared to $1.9 million recognized in the same period in 2013. The decrease in revenues from 2013 to 2014 was primarily due to funding of clinical support from former partner, GlaxoSmithKline (GSK), for CCX168, our C5aR inhibitor, in 2013. ChemoCentryx’s product development and commercialization agreement with GSK ended in November 2013, and therefore no revenue was recorded in 2014. ChemoCentryx Inc (NASDAQ:CCXI), ended the last trading day at $5.22. Company weekly volatility is calculated as 5.25% and price to cash ratio as 1.70. ChemoCentryx Inc (NASDAQ:CCXI), showed a negative weekly performance of 3.69%.
On May 05, 2014, ANI Pharmaceuticals Inc (NASDAQ:ANIP), reported financial results for the three months ended March 31, 2014. For the three months ended March 31, 2014, ANI reported net revenues of $10.9 million, an increase of 96% from $5.6 million in the prior year period. The increase in revenues was primarily due to a 150% increase in net prescription sales from $3.5 million to $8.8 million, primarily due to increased sales of and price increases for ANI’s Esterified Estrogen with Methyltestosterone Tablet (“EEMT”) product. Development services and royalty revenues also increased by $0.2 million, or 54%. This was partially offset by a 7% decrease in contract sales, from $1.7 million to $1.6 million. ANI Pharmaceuticals Inc (NASDAQ:ANIP), net profit margin is -23.30% and weekly performance is -3.69%. On last trading day company shares ended up $29.24. Analysts mean target price for the company is $39.00. ANI Pharmaceuticals Inc (NASDAQ:ANIP), distance from 50-day simple moving average (SMA50) is -3.95%.